Glucose tracking
made easy.1
Personalized insights from Stelo help
patients achieve their glucose goals
and make health a habit.*,1-4
No prescription. No fingersticks. Just results.
Empower patients with personalized insights.1
For patients who want to understand how lifestyle and behavior
modifications impact glucose levels.*,1-4
Stelo glucose biosensor is for patients with1-4:
- Type 2 diabetes not on insulin
- Prediabetes
- An interest in tracking their glucose for health insights
And for patients who want to*,1-5:
- Spend more time in their target glucose range for better A1C control
- Stay healthy or improve their health by better understanding
how lifestyle and behavior modifications impact glucose levels - Make healthy choices become healthy habits
- Get the most out of their glucagon-like peptide-1 (GLP-1) agonists
Personalized insights. Personal success.1
Individualized feedback drives better understanding of glucose health,
empowering patients to achieve their glucose goals*,1-4
Biosensing that makes sense*,1-4
Continuous glucose tracking helps patients understand the
relationship between diet, exercise, and glucose levelsStelo is designed to support and motivate patients and create
lasting behavior change
Tailored insights promote patient
understanding*,1-4
Insights tailored to a patient’s individual needs empower them
to retake control over their glucose24/7 access to personalized glucose insights helps patients
uncover what works for them
Real outcomes with glucose sensors like Stelo
- Reduction of A1C*,4
- Users spend up to 17.3% more time in range and 16% more time in tight range*,6
- Significant improvements in glucose and cardiovascular risk-
reduction measures*†,2
Glucose health benefits are achieved within 3-6 months and are sustained with ongoing glucose sensor use*,6
- Use may slow the progression of diabetes*,5,6,8-10
- Improved lifestyle behaviors, particularly diet*,1-4
Order for your practice and bring the benefit of Stelo to your patients
Patients can order online and use HSA/FSA benefits to purchase Stelo
*Results obtained from previous Dexcom device(s) in patients with diabetes. †For adults 18 years and older who are not on insulin and who are not at risk of problematic hypoglycemia. ‡Both single and dual agonists. §Cardiovascular risk refers to 10-year ASCVD risk. Visit https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate to access the American College of Cardiology ASCVD Risk Estimator Plus.
1 Stelo User Guide. 2 Ehrhardt N, et al. Clin Diab. 2020;38(2):1-6. 3 Porter M, et al. J Diabetes Sci Technol. 2022;16(2):578-580. 4 Polonsky W, et al. Diabetes Technol Ther. 2024;26(suppl 2):A47. 5 Layne JE, et al. Diabetes Technol Ther. 2024. doi: 10.1089/dia.2024.0197 6 Reed J, et al. Diabetes Obes Metab. 2024;26(7):2881-2889. 7 Nemlekar PM, et al. Diabetes Technol Ther. 2024;26(suppl 2):A206-A207. 8 Battelino T, et al. Diabetes Care. 2019;42(8):1593-1603. 9 Vigersky RA, et al. Diabetes Technol Ther. 2019;21(2):81-85. 10 UKPDS Group. Lancet. 1998;352(9131):837-853.